Actinium Pharmaceuticals Receives NYSE American Compliance Plan Approval

What happened

Actinium Pharmaceuticals, Inc., a New York-based company developing cancer treatments, disclosed in an SEC filing on August 14, 2026, that NYSE Regulation accepted its plan to regain compliance with NYSE American listing standards.

The company had received a notice on May 27, 2026, that it was not in compliance with Sections 1003(a)(ii) and (iii) of the NYSE American Company Guide, which relate to minimum stockholders' equity and continued listing requirements. It submitted a compliance plan on June 18, 2026.

On August 12, 2026, NYSE Regulation accepted the plan and granted the company a period through November 27, 2027 — the maximum available — to regain compliance. During this period, the company's common stock will continue to trade on NYSE American under the symbol 'ATNM.'

Shares rose 7.88% on the news, closing at $1.04, with volume about four times the average.

What this means

An 8-K is a current report that companies file with the SEC to announce major events, including listing rule failures. Item 3.01 of the form is specifically for notifying investors of delisting or failure to meet continued listing standards, and Item 7.01 covers Regulation FD disclosures, which is how the company shared its press release.

Sections 1003(a)(ii) and (iii) of the NYSE American Company Guide require listed companies to maintain a minimum amount of stockholders' equity and, in some cases, a minimum level of operations. When a company falls short, NYSE American can initiate delisting, but it often allows the company to submit a plan showing how it will fix the issue.

The acceptance of the plan means the company has been granted an extension — until November 27, 2027 — to meet the standards. During this period, NYSE Regulation will periodically review the company's progress. If it does not make progress or fails to regain compliance by the deadline, delisting proceedings may begin.

This is not a delisting notice; it is the opposite — confirmation that the exchange is allowing the company to stay listed while it works to fix the problem.

What this means

The company's stock remains listed, but the situation is not resolved. The company must now execute on the compliance plan and meet the listing standards by the end of the plan period. If it fails to do so, NYSE Regulation can begin delisting proceedings, which would remove the stock from the exchange.

This news is important for investors because it removes the immediate threat of delisting, but the company still faces the underlying financial issues that caused the noncompliance.